Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1355, 2002-01, pp. : 8-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Natalizumab: multiple benefits in multiple sclerosis
Inpharma, Vol. 1, Iss. 1487, 2005-01 ,pp. :
Access to resources
Recommend
Eptifibatide has long-term benefits post-PCI
Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. :
Natalizumab benefits QOL in multiple sclerosis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 577, 2009-01 ,pp. :
Cilengitide, an integrin antagonist, has shown potential in the treatment of malignant glioma
Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. :